ESSA Pharma is Flying on Updated Phase 1/2 Study Results Announcement

(24/7 MARKET NEWS) – ESSA Pharma Inc. (NASDAQ: EPIX) took off a little late, but is more than making up by flying fast and hard, on news that the updated results from the Phase 1/2 Study of its Lead Candidate EPI-7386, in combination with Enzalutamide, will be highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat.

ESSA Pharma is trading at $2.75, up $1.03 (+59.88%), on nearly 17 million shares.

Its 52-week range is $1.40 to $14.88. It’s traded at $2.95 and its next significant inflection point is about $3.65, as the following resistance levels appear to be weaker.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist